ATHA - Athira Pharma Inc Analyst Forecast Prices
Athira Pharma, Inc. (ATHA) focuses on developing small molecules for the therapy of Parkinson's and Alzheimer's diseases, aiming to restore neural connections. The market trend on GURU.Markets, which currently stands at 4.00, confirms interest in assets with protected patents and stable demand. The continuity of development is ensured by strict temperature control during the transportation of biochemical components.
Analytical breakdowns for Athira (ATHA)
- stock value and consensus price forecast:
- market capitalization statistics:
- book capitalization information:
- debt obligations and liquidity statistics:
Debt to Equity Ratio Athira Pharma, Inc.|ATHA - Long-Term Debt to Capital|Current Liabilities to Capital Athira Pharma Corp|ATHA - Company Total Debt|Debts to Book Capitalization Athira|ATHA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Athira Pharma|Immediate Liquidity athira.com
- earnings and valuation multiples information:
ATHA - Net Profit|Projected Future Earnings Athira Pharma, Inc.|ATHA - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Athira Pharma Inc|ATHA - PEG Multiple|Business Value to Operating Income Before Depreciation Athira|ATHA - Operating profit EBITDA|Net earnings per share for the last four quarters Athira Pharma|ATHA - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months athira.com|ATHA - Earnings growth in current year|Earnings growth forecast for next year Athira Pharma, Inc.
Summary company analytics:ATHA athira.com
The prospects of Athira Pharma, Inc. (ATHA) depend on the commercial success of drugs for the regeneration of neural connections in neurodegenerative diseases. The trend in analyst price targets reflects a revision of the asset's fair value in light of macro-inflation and liquidity, allowing investors to assess the extent of the issuer's overvaluation and its sensitivity to interest rate changes during periods of market volatility.
Competitors of Athira Pharma, Inc.
Analyst Consensus Forecast biogen.com (BIIB)|Neurocrine Biosciences, Inc. - Consensus Target|Analyst Forecast Prices RGC (Regencell Bioscience Ltd)|Axsome Therapeutics Inc - Analyst Consensus Forecast|Fair Value Consensus ACAD (ACADIA Corp)|XENE: Analyst Consensus Forecast|vikingtherapeutics.com (VKTX) - Analyst Consensus Forecast|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|PRTA (Prothena Corporation PLC) - Analyst Consensus Forecast|Analyst Consensus Forecast Alector Therapeutics|Consensus Target ANNX (Annexon)|Analyst Forecast Prices OMER|Analyst Consensus Forecast NGNE (Neurogene Corp)|Fair Value Consensus ACIU|Voyager Therapeutics - Analyst Consensus Forecast|Analyst Median Target neumoratx.com NMRA|Scilex (SCLX) - Price Target Chart|Tevogen Bio Holdings Inc. - Fair Value Consensus|ACOG (Alpha Cognition Inc) - Analyst Consensus Forecast|Analyst Consensus Forecast cogrx.com|Consensus Target IKT (Inhibikase Therapeutics)|SAVA (cassavasciences.com) - Fair Value Consensus|Price Target Chart Assertio ASRT|COYA (Coya Therapeutics Inc) - Forecast Levels Chart|VistaGen Therapeutics Inc - Analyst Consensus Forecast|Fair Value Consensus OVID (Ovid Therapeutics Inc.)|ABOS: Analyst Consensus Forecast|cervomed.com (CRVO) - Analyst Consensus Forecast|Price Target Chart Alterity Therapeutics Ltd.|CLNN: Fair Value Consensus|Price Target Chart PepGen Inc. (PEPG)|Consensus Target jupiterneurosciences.com JUNS|Analyst Consensus Forecast RLMD (Relmada Therapeutics)|Analyst Consensus Forecast annovisbio.com ANVS|GRCE: Consensus Target|Fair Value Consensus AIFF (Firefly Neuroscience, Inc.)|KLTO: Analyst Consensus Forecast|NRSN - Analyst Median Target|Price Target Chart Reviva Pharmaceuticals|Broker Consensus Forecast MTVA (MetaVia, Inc.)|Analyst Consensus Forecast NRXS|Consensus Target heliusmedical.com HSDT|Passage Bio - Consensus Target|Analyst Median Target Neuphoria Therapeutics, Inc. (NEUP)|Minerva Neurosciences - Analyst Consensus Forecast|ADXN - Analyst Consensus Forecast|ALZN (alzamend.com) - Consensus Target|CYCN: Analyst Forecast Prices|PTIX (Protagenic Therapeutics Inc.) - Analyst Consensus Forecast|KTTA: Fair Value Consensus|Analyst Consensus Forecast CRGT|Analyst Consensus Forecast avenuetx.com (ATXI)|Price Target Chart BrainStorm Cell Therapeutics BCLI|CARA: Broker Consensus Forecast|Chromocell Therapeutics Corporation - Analyst Consensus Forecast|Average Forecast Price Eliem Therapeutics|ITCI (intracellulartherapies.com) - Consensus Target|longboardpharma.com (LBPH) - Analyst Consensus Forecast|Price Target Chart Marinus Pharmaceuticals, Inc.|NKGN: Fair Value Consensus|Price Target Chart NeuroBo (NRBO)|SAGE - Average Forecast Price|Analyst Consensus Forecast SNPX (Synaptogenix, Inc.)|Analyst Consensus Forecast trevena.com TRVN|VIGL: Consensus Target|Anew Medical Inc. - Analyst Forecast Prices|CERE: Analyst Consensus Forecast
